stockrow
Friday 6 November 2026
Export FLGT’s income statement to Excel — free account
Fulgent Genetics, Inc.
FLGT Healthcare Diagnostics & Research
Fulgent Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $322.7 million, up 13.8% from fiscal 2024.
- Revenue
- +7.54%
- EPS
- −128.6%
- Free cash flow
- +2,058.7%
Quarter to September 2026, against a year earlier
18.66
1.02
−5.18%
Follow FLGT
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 6.48 | 5.81 | 5.97 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
4 | 6 | 4 | 5 | 5 | 6 | 6 | 4 | 5 | 6 |
P/S ratio |
2.51 | 1.97 | 3.02 | 1.49 | 2.98 | 2.80 | 7.42 | 2.67 | 4.01 | 8.36 |
Altman Z-Score |
5.63 | 4.68 | 5.91 | 6.78 | 19.45 | 8.36 | 24.02 | 11.69 | 14.85 | 26.24 |
P/FCF ratio |
0.00 | 0.00 | 156.59 | 3.92 | 5.75 | 11.21 | 55.67 | 0.00 | 0.00 | 243.81 |
Altman Z″-Score (non-manufacturers) |
14.32 | 15.74 | 14.58 | 16.78 | 18.68 | 11.73 | 14.64 | 19.55 | 18.66 | 15.65 |
P/Operating CF |
(10.35) | 22.32 | 58.42 | 27.79 | 38.37 | 8.81 | (2,080.57) | 73.25 | (60.46) | 121.90 |
Beneish M-Score |
(2.35) | (1.99) | (2.55) | (3.70) | (1.34) | 8.62 | (1.53) | (2.66) | (2.97) | (0.29) |
P/B ratio |
0.73 | 0.49 | 0.77 | 0.73 | 2.54 | 2.08 | 2.92 | 1.11 | 1.39 | 2.81 |
Price to Tangible BV |
0.80 | 0.54 | 0.90 | 0.95 | 2.74 | 2.08 | 2.92 | 1.11 | 1.39 | 2.81 |
EV/Sales |
1.53 | 1.13 | 1.62 | 0.67 | 2.55 | 2.13 | 6.63 | 1.22 | 2.59 | 7.22 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 1.93 | 3.64 | 3.06 | 120.87 | 0.00 | 0.00 | 61.37 |
EV/Operating CF |
(4.85) | 15.26 | 17.37 | 1.65 | 4.70 | 6.39 | 39.11 | (38.45) | 36.48 | 29.97 |
EV/FCF |
(3.97) | (16.96) | 84.22 | 1.78 | 4.91 | 8.52 | 49.77 | (7.40) | (12.06) | 210.52 |
Quick Ratio |
4.95 | 4.49 | 6.51 | 6.57 | 5.60 | 3.71 | 9.35 | 13.51 | 10.16 | 7.61 |
Current Ratio |
6.48 | 4.85 | 6.96 | 7.13 | 5.81 | 4.02 | 9.96 | 14.44 | 10.98 | 7.88 |
Net Debt/EBITDA |
4.66 | 4.73 | 7.99 | (2.37) | (0.63) | (0.97) | (15.84) | 11.89 | 19.14 | (9.70) |
Debt/Assets |
0.00% | 0.00% | 0.00% | 1.08% | 1.18% | 2.14% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.27 | 0.23 | 0.22 | 0.46 | 1.00 | 1.07 | 0.46 | 0.38 | 0.33 | 0.57 |
Operating CF/Net income |
1.68 | (0.49) | (0.16) | 1.77 | 1.06 | 0.66 | (13.42) | 0.12 | (0.53) | (0.32) |
Capex/Depreciation |
(1.19) | (2.06) | (0.15) | (0.49) | (1.28) | (9.20) | (0.53) | (1.15) | (2.55) | (3.06) |
Interest Coverage |
(1,214.61) | 434.81 | (400.67) | 176.24 | 519.96 | 193.44 | (0.49) | (8.77) | (7.62) | — |
| (5.41%) | (3.78%) | (13.97%) | 11.77% | 58.48% | 65.72% | (0.61%) | (10.65%) | (4.62%) | (45.84%) | |
| (4.97%) | (3.48%) | (12.80%) | 10.76% | 51.27% | 54.31% | (0.58%) | (10.09%) | (4.36%) | (42.79%) | |
ROIC |
(7.39%) | (5.30%) | (17.23%) | 14.71% | 57.83% | 63.62% | (0.49%) | (15.75%) | (7.86%) | 1.71% |
Return on Tangible Assets |
(10.47%) | (11.06%) | (32.38%) | 23.09% | 89.18% | 49.41% | (1.05%) | (12.96%) | (6.75%) | (47.03%) |
Average Days of Receivables |
95.88 | 88.87 | 64.53 | 31.11 | 51.08 | 159.13 | 73.55 | 101.68 | 78.05 | 87.16 |
Research and Development Expense of Revenue |
16.71% | 17.22% | 14.33% | 4.67% | 2.44% | 2.75% | 20.10% | 25.92% | 22.55% | 19.47% |
Selling, General and Administrative Expense of Revenue |
49.60% | 43.87% | 45.11% | 24.23% | 7.57% | 7.15% | 37.85% | 47.73% | 50.39% | 38.73% |
Intangible Assets out of Total Assets |
0.07 | 0.08 | 0.13 | 0.21 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
12.27% | 15.69% | 14.84% | 5.27% | 1.60% | 1.93% | 9.87% | 10.79% | 11.31% | 25.47% |
Graham Net Nets |
0.55 | 0.47 | 0.47 | 0.55 | 0.17 | 0.33 | 0.13 | 0.65 | 0.40 | 0.15 |
Graham Number |
0.00 | 0.00 | 0.00 | 67.01 | 124.26 | 70.16 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(7.46%) | (7.63%) | (19.26%) | 15.43% | 17.21% | 16.74% | (0.11%) | (9.89%) | (3.58%) | (3.98%) |
Free Cash Flow Yield |
(15.36%) | (3.39%) | 0.64% | 25.48% | 17.40% | 8.92% | 1.80% | (6.15%) | (5.36%) | 0.41% |
Revenue per Share |
10.48 | 9.38 | 9.71 | 20.57 | 33.75 | 18.58 | 1.74 | 1.19 | 1.06 | 1.33 |
Operating CF per Share |
(3.30) | 0.70 | 0.91 | 8.42 | 18.31 | 6.20 | 0.29 | (0.04) | 0.08 | 0.32 |
Capex per Share |
(0.73) | (1.32) | (0.72) | (0.61) | (0.81) | (1.55) | (0.06) | (0.16) | (0.30) | (0.28) |
Free Cash Flow per Share |
(4.04) | (0.63) | 0.19 | 7.81 | 17.51 | 4.65 | 0.23 | (0.20) | (0.23) | 0.05 |
Cash per Share |
10.92 | 8.54 | 14.24 | 17.48 | 15.32 | 13.19 | 1.51 | 1.73 | 1.49 | 1.52 |
Shareholders Equity per Share |
35.96 | 37.35 | 38.05 | 42.19 | 39.65 | 25.09 | 4.42 | 2.85 | 3.05 | 3.97 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
35.96 | 37.35 | 38.05 | 42.19 | 39.65 | 25.09 | 4.42 | 2.85 | 3.05 | 3.97 |
Free Cash Flow |
(124.21) | (18.94) | 5.57 | 235.16 | 514.80 | 105.51 | 4.34 | (3.51) | (4.02) | 0.63 |
Working Capital |
465.52 | 280.67 | 434.83 | 539.77 | 506.65 | 393.50 | 33.36 | 36.81 | 29.93 | 22.82 |
Capital Expenditures |
(22.57) | (40.00) | (21.43) | (18.36) | (23.78) | (35.12) | (1.18) | (2.83) | (5.36) | (3.78) |
Net Current Asset Value |
443.68 | 262.77 | 405.80 | 511.70 | 499.12 | 392.54 | 31.10 | 36.79 | 29.92 | 22.58 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 2.34 | 3.74 | 3.10 | 0.00 | 0.00 | 0.00 | 143.79 |
Capex to Sales |
0.07 | 0.14 | 0.07 | 0.03 | 0.02 | 0.08 | 0.04 | 0.13 | 0.29 | 0.21 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 5.17 | 4.38 | 4.07 | 0.00 | 0.00 | 0.00 | 166.52 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.17 | 0.18 | 1.71 | 0.46 | 0.30 | 0.10 | 0.37 | 0.38 | 0.29 | 0.20 |
Cash ROIC |
(8.61%) | (1.37%) | 0.36% | 12.98% | 31.55% | 11.94% | 3.90% | (4.27%) | (4.99%) | 0.83% |
Accounts Receivable Turnover |
4.20 | 4.72 | 5.57 | 6.46 | 6.15 | 4.43 | 5.20 | 4.29 | 4.48 | 5.64 |
Accounts Payable Turnover |
10.36 | 10.45 | 9.61 | 11.57 | 9.18 | 6.40 | 9.75 | 6.29 | 3.53 | 4.38 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
35.50 | 38.03 | 30.34 | 33.44 | 34.71 | 107.65 | 40.91 | 44.80 | 89.17 | 149.65 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
76.89 | 60.08 | 51.94 | 95.83 | 161.38 | 95.21 | 6.25 | 4.98 | 4.18 | 3.24 |
Average Payables |
18.51 | 16.86 | 19.23 | 21.79 | 23.49 | 14.03 | 1.45 | 1.70 | 2.42 | 1.54 |
Average Assets |
1,216.74 | 1,227.65 | 1,310.69 | 1,332.39 | 989.59 | 394.61 | 71.33 | 55.54 | 57.61 | 31.94 |
Average Common Equity |
1,117.94 | 1,131.22 | 1,201.58 | 1,217.88 | 867.63 | 326.08 | 66.96 | 52.67 | 54.33 | 29.81 |
Columns are period end dates · fundamentals updated 5 Nov 2026